Literature DB >> 6846258

Laboratory diagnosis of lupus inhibitors: a comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure.

D A Triplett, J T Brandt, D Kaczor, J Schaeffer.   

Abstract

The introduction of the activated partial thromboplastin time (APTT) as a screening test has resulted in increased recognition of circulating anticoagulants. The most frequently encountered inhibitor is the lupus-type anticoagulant. However, criteria for differentiation of this inhibitor are not well-established. We evaluated the ability of two procedures, tissue thromboplastin inhibition (TTI) and a new platelet neutralization procedure (PNP), to differentiate between various types of coagulation inhibitors. The TTI, widely used for the diagnosis of lupus anticoagulants, proved to be nonspecific. The PNP specifically separated lupus-type inhibitors from Factor VIII, X, and V inhibitors. The PNP may be a useful test for the diagnosis of lupus anticoagulants.

Mesh:

Substances:

Year:  1983        PMID: 6846258     DOI: 10.1093/ajcp/79.6.678

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  19 in total

Review 1.  Drug-induced lupus anticoagulants and antiphospholipid antibodies.

Authors:  Jeffrey S Dlott; Robert A S Roubey
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

2.  Ocular involvement in primary antiphospholipid syndrome. Ocular involvement in primary APS.

Authors:  F Y Demirci; R Küçükkaya; K Akarçay; N Kir; T Atamer; H Demirci; E Ongör
Journal:  Int Ophthalmol       Date:  1998       Impact factor: 2.031

3.  Addison's disease, hypertension, renal and hepatic microthrombosis in 'primary' antiphospholipid syndrome.

Authors:  S Inam; K Sidki; A R al-Marshedy; R Judzewitsch
Journal:  Postgrad Med J       Date:  1991-04       Impact factor: 2.401

Review 4.  Influence of the lupus anticoagulant on clotting tests.

Authors:  J Vermylen; J Arnout
Journal:  Clin Rheumatol       Date:  1990-03       Impact factor: 2.980

5.  Guidelines on testing for the lupus anticoagulant. Lupus Anticoagulant Working Party on behalf of the BCSH Haemostasis and Thrombosis Task Force.

Authors: 
Journal:  J Clin Pathol       Date:  1991-11       Impact factor: 3.411

6.  Lupus anticoagulant: clinical significance in anticardiolipin positive patients with systemic lupus erythematosus.

Authors:  N J McHugh; D A Moye; I E James; M Sampson; P J Maddison
Journal:  Ann Rheum Dis       Date:  1991-08       Impact factor: 19.103

Review 7.  Detection of lupus anticoagulants.

Authors:  M H Horellou; M M Samama
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

8.  Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes.

Authors:  M A Khamashta; E N Harris; A E Gharavi; G Derue; A Gil; J J Vázquez; G R Hughes
Journal:  Ann Rheum Dis       Date:  1988-10       Impact factor: 19.103

9.  Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients.

Authors:  R H Derksen; P Hasselaar; L Blokzijl; F H Gmelig Meyling; P G De Groot
Journal:  Ann Rheum Dis       Date:  1988-05       Impact factor: 19.103

10.  Arterial thrombotic manifestations in young women associated with the lupus anticoagulant.

Authors:  E J Ter Borg; J Van der Meer; J T De Wolf; M H Van Leeuwen; C G Kallenberg
Journal:  Clin Rheumatol       Date:  1988-03       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.